04:18 AM EST, 01/30/2025 (MT Newswires) -- MaxCyte ( MXCT ) said Thursday it has acquired SeQure Dx for $4.5 million in upfront cash and up to $2.5 million in contingency payments.
SeQure Dx provides on-target and off-target editing assessment services for cell and gene therapies.
MaxCyte ( MXCT ) expects the deal to be accretive to its revenue growth.